New antibody aims to quiet seizures
NCT ID NCT07051629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called SIF001, a monoclonal antibody designed to treat epilepsy. Researchers are giving the drug to healthy volunteers and people with epilepsy to check its safety, how the body processes it, and what side effects may occur. The study uses a placebo for comparison and gradually increases the dose to find the safest range.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIF001 (a monoclonal antibody)
What this could lead to
If safe and effective, SIF001 could offer a new way to control seizures in people with epilepsy.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet on effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accel Research sites network
RECRUITINGDeLand, Florida, 32720, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Center for Neurosciences
RECRUITINGTucson, Arizona, 85718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
D&H Tamarac Research Center, LLC
RECRUITINGTamarac, Florida, 33321, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dent Neurologic Institute
RECRUITINGAmherst, New York, 14226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Encore Medical Research of Weston, LLC
RECRUITINGWeston, Florida, 33331, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center
RECRUITINGHonolulu, Hawaii, 96817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Horizon Clinical Research Center
RECRUITINGCypress, Texas, 77429, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mid-Atlantic Epilepsy and Sleep Center
RECRUITINGBathesda, Maryland, 20817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OnSite Clinical Solutions, LLC
RECRUITINGCharlotte, North Carolina, 28277, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Quest Research Institute
RECRUITINGFarmington Hills, Michigan, 48334, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••